D
David Matthew Wilson
Researcher at AstraZeneca
Publications - 106
Citations - 4895
David Matthew Wilson is an academic researcher from AstraZeneca. The author has contributed to research in topics: Benzazepine & Histamine H3 receptor. The author has an hindex of 27, co-authored 106 publications receiving 4037 citations. Previous affiliations of David Matthew Wilson include GlaxoSmithKline & Virginia Tech.
Papers
More filters
Journal ArticleDOI
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response
Laurens Kruidenier,Chun-wa Chung,Zhongjun Cheng,John Liddle,K.H. Che,K.H. Che,Gerard Joberty,Marcus Bantscheff,C. Bountra,Angela Bridges,Hawa Diallo,Dirk Eberhard,Sue Hutchinson,Emma J. Jones,Roy Katso,Melanie Leveridge,Palwinder K. Mander,J. Mosley,Cesar Ramirez-Molina,Paul Rowland,Christopher J. Schofield,Robert J. Sheppard,Julia Smith,Catherine Swales,Robert Tanner,Pamela Thomas,Anthony Tumber,Gerard Drewes,Udo Oppermann,Udo Oppermann,Dinshaw J. Patel,Kevin Lee,Kevin Lee,David Matthew Wilson +33 more
TL;DR: It is demonstrated that the first small-molecule catalytic site inhibitor that is selective for the H3K27me3-specific JMJ subfamily binds in a novel manner and reduces lipopolysaccharide-induced proinflammatory cytokine production by human primary macrophages, a process that depends on both JMJD3 and UTX.
Journal ArticleDOI
Organic synthesis provides opportunities to transform drug discovery
David C. Blakemore,Luis Castro,Ian Churcher,David C. Rees,Andrew Thomas,David Matthew Wilson,Anthony Wood +6 more
TL;DR: This Perspective highlights some of the most pressing challenges to be overcome from the industrial viewpoint — such as the development of reactions tolerating specific functionalities — and encourages stronger industry–academia relationships.
Journal ArticleDOI
Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation
Huw D. Lewis,John Liddle,Jim E Coote,Stephen John Atkinson,Michael David Barker,Benjamin D. Bax,Kevin L. Bicker,Ryan P. Bingham,Matthew Campbell,Yu Hua Chen,Chun-wa Chung,Peter D. Craggs,Robert P. Davis,Dirk Eberhard,Gerard Joberty,Kenneth E Lind,Kelly Locke,Claire Maller,Kimberly Martinod,Chris Patten,Oxana Polyakova,Cecil E Rise,Martin Rüdiger,Robert J. Sheppard,Daniel J. Slade,Pamela Thomas,Jim Thorpe,Gang Yao,Gerard Drewes,Denisa D. Wagner,Paul R. Thompson,Rab K. Prinjha,David Matthew Wilson +32 more
TL;DR: Novel, selective PAD4 inhibitors binding to a calcium-deficient form of the PAD3 enzyme have been validated, for the first time, in both histone citrullination and neutrophil extracellular trap formation, validating the critical enzymatic role of human and mouse PAD 4.
Journal ArticleDOI
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.
Adriana E. Tron,Matthew A. Belmonte,Ammar Adam,Brian Aquila,Brian Aquila,Lawrence H. Boise,Elisabetta Chiarparin,Justin Cidado,Kevin J. Embrey,Eric Gangl,Francis D. Gibbons,Gareth P. Gregory,Gareth P. Gregory,David J. Hargreaves,J. Adam Hendricks,Jeffrey W. Johannes,Ricky W. Johnstone,Ricky W. Johnstone,Steven L. Kazmirski,Jason Grant Kettle,Michelle Lamb,Shannon M. Matulis,Ajay K. Nooka,Martin J. Packer,Bo Peng,Philip B. Rawlins,Daniel W. Robbins,Alwin Schuller,Nancy Su,Wenzhan Yang,Qing Ye,Xiaolan Zheng,J. Paul Secrist,Edwin Clark,David Matthew Wilson,Stephen Fawell,Alexander Hird +36 more
TL;DR: AZD5991 is a macrocyclic molecule with high selectivity and affinity for Mcl-1 that exhibits potent anti-tumor effects as single agent and in combination with bortezomib or venetoclax in preclinical models of multiple myeloma and acute myeloid leukemia.
Journal ArticleDOI
GSK189254, a Novel H3 Receptor Antagonist That Binds to Histamine H3 Receptors in Alzheimer's Disease Brain and Improves Cognitive Performance in Preclinical Models
Andrew D. Medhurst,Alan R. Atkins,Isabel J. M. Beresford,Kim Brackenborough,Michael A. Briggs,Andrew R. Calver,Jackie Cilia,Jane E. Cluderay,Barry Crook,John B. Davis,Rebecca K. Davis,Robert P. Davis,Lee A. Dawson,Andrew G. Foley,Jane Gartlon,M. Isabel Gonzalez,Teresa Heslop,Warren D. Hirst,Carol A. Jennings,Declan N.C. Jones,Laurent Lacroix,Abbe Martyn,Sandrine Ociepka,Alison M. Ray,Ciaran M. Regan,Jennifer C. Roberts,Joanne Schogger,Eric Southam,Tania O. Stean,Brenda K. Trail,Neil Upton,Graham Wadsworth,Jeffrey Wald,Trevor White,Jason Witherington,Marie L. Woolley,Angela Worby,David Matthew Wilson +37 more
TL;DR: Dense H3 binding was detected in medial temporal cortex samples from severe cases of Alzheimer's disease, suggesting for the first time that H3 receptors are preserved in late-stage disease.